General Information of the Compound
| Compound ID |
CP0010658
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Show/Hide
|
||||||||||||||||||
| Synonyms |
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
139755-83-2
3M7OB98Y7H
5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
BNRNXUUZRGQAQC-UHFFFAOYSA-N
C22H30N6O4S
CHEBI:9139
CHEMBL192
HSDB 7305
Rhucin
Sildenafil
Sildenafil [INN:BAN]
UK 92480-10
UK-92,480-10
UK-92480
UNII-3M7OB98Y7H
VIAGRA
sildenafil
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C22H30N6O4S
|
||||||||||||||||||
| Molecular Weight |
474.587
|
||||||||||||||||||
| Canonical SMILES |
CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
Show/Hide
|
||||||||||||||||||
| InChIKey |
BNRNXUUZRGQAQC-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
139755-83-2
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00862, Adenosine receptor A2a
Protein ID: PT05334, ATP-binding cassette sub-family C member 4
Protein ID: PT06399, ATP-binding cassette sub-family C member 5
Protein ID: PT01875, cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Protein ID: PT02047, cGMP-dependent 3',5'-cyclic phosphodiesterase
Protein ID: PT01176, cGMP-specific 3',5'-cyclic phosphodiesterase
Cell-based Assay
Protein ID: PT02485, cGMP-specific 3',5'-cyclic phosphodiesterase
Protein ID: PT03334, Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'
Protein ID: PT02504, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
Protein ID: PT06109, Geminin
Protein ID: PT02393, High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A
Protein ID: PT03075, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
Protein ID: PT03388, Indoleamine 2,3-dioxygenase 1
Protein ID: PT06300, Indoleamine 2,3-dioxygenase 2
Protein ID: PT00897, Potassium voltage-gated channel subfamily H member 2
Cell-based Assay
Protein ID: PT01102, Voltage-dependent L-type calcium channel subunit alpha-1C
Clinical Information about the Compound
Drug 1 ( Rhucin )
| Drug Name | Rhucin | ||
|---|---|---|---|
| Company | Pfizer | ||
| Indication | |||
| Target(s) |
Phosphodiesterase 5A (PDE5A)
Inhibitor
|
||